— Know what they know.
Not Investment Advice

CLYM NASDAQ

Climb Bio, Inc.
1W: -3.7% 1M: +17.3% 3M: +93.8% YTD: +190.9% 1Y: +779.8%
$11.00
+0.09 (+0.82%)
 
Weekly Expected Move ±12.3%
$8 $9 $11 $12 $13
NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 62 · $750.0M mcap · 60M float · 1.17% daily turnover · Short 36% of daily vol
Smart Money Score
Moderate 50
Insider+$0.8M
Congress
ETF Holdings
Key Statistics
Market Cap$750.0M
52W Range1.16-12.48
Volume467,199
Avg Volume701,615
Beta0.05
Dividend
Analyst Ratings
5 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOAoife Brennan BCh MMSc
Employees17
SectorHealthcare
IndustryBiotechnology
IPO Date2021-08-10
PMB #117, 2801 Centerville Road
Wellesley Hills, DE 19808-1609
US
866 857 2596
About Climb Bio, Inc.

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Recent Insider Trades

NameTypeSharesPriceDate
Thomas Stephen Basil S-Sale 16,313 $7.01 2026-02-26
Thomas Stephen Basil S-Sale 33,687 $7.00 2026-02-25
Thomas Stephen Basil S-Sale 10,000 $5.81 2026-02-13
Thomas Stephen Basil S-Sale 90,000 $5.23 2026-02-12
Brennan Aoife A-Award 700,000 $3.81 2026-01-06

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms